Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADILW), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals (ADILW) focuses on developing personalized treatments for addiction disorders through advanced pharmacogenomics. This news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives driving innovation in addiction medicine.
Access timely information about clinical trial results, FDA communications, and research partnerships directly impacting the company's progress. Our curated collection includes press releases on AD04's development, patent updates, and scientific presentations while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to verified ADILW announcements. Check regularly for updates on groundbreaking approaches to alcohol and opioid use disorder treatments that combine genetic targeting with therapeutic innovation.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced on February 24, 2023, that it will conduct a $0.75 million registered direct offering of common stock. The purchase price is set at $0.41 per share, totaling 1,829,269 shares to be sold. The offering is arranged through Joseph Gunnar & Co., LLC as the placement agent and is expected to close on February 24, 2023, pending customary conditions. The offering is registered under an effective Form S-3 registration statement with the SEC, and a prospectus supplement will be filed to provide further details.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced plans for significant regulatory meetings in 2023, including a Type C meeting with the FDA in the second quarter. These discussions aim to advance clinical development for AD04, targeting alcohol use disorder (AUD). The company is also engaging with five European regulatory authorities, seeking guidance toward expedited approvals. CEO Cary Claiborne emphasized these meetings as crucial for completing AD04's development and exploring potential partnerships for funding and market strategies. The ONWARD™ Phase 3 trial showed promising results for AD04, potentially expanding its use to other addictions.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a strategic focus on the late-stage development of AD04 for Alcohol Use Disorder (AUD) while potentially selling its subsidiary, Purnovate, to a new entity led by former CEO William Stilley. This option agreement allows Adenomed to purchase Purnovate's assets for $450,000, with Adial eligible for up to $83 million in milestones and royalties. The deal aims to reduce Adial's burn rate and extend its cash runway. Stilley plans to maximize Purnovate's drug candidates' value, emphasizing the potential of adenosine technology in unmet medical needs.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is advancing its regulatory strategy for AD04, following promising Phase 3 ONWARD™ trial results for treating Alcohol Use Disorder (AUD). The company aims for commercialization in Europe and North America, positively impacting millions with AUD. Adial also reported financial results for Q3 2022, with a reduced net loss of $3.1 million ($0.12/share), down from $4.3 million in Q3 2021. Additionally, R&D expenses decreased by 26% to $1.3 million, while general and administrative costs fell by 18% to $1.9 million, highlighting improved cost management.
Adial Pharmaceuticals announced positive results for PNV-5030, a treatment for chronic pain, demonstrating significant pain reduction in animal models. In a study involving rats, PNV-5030 reduced pain by up to 76% compared to placebo and showed higher efficacy than acetaminophen. The drug exhibited over 1000-fold selectivity over the A1 receptor and improved solubility by more than 50 times compared to similar compounds. This breakthrough could lead to advancements toward human clinical trials, enhancing Adial's drug development pipeline.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has reported promising results for its PNV-6005, a selective adenosine 2A receptor agonist, in treating ulcerative colitis in an animal model. The study showed that PNV-6005 significantly reduced weight loss (over 50% inhibition) and prevented colon damage, suggesting strong anti-inflammatory properties. Conducted by experts at UC San Diego, the research aligns with Adial's strategy to advance this candidate towards human clinical trials amid a growing ulcerative colitis market projected to reach $10.8 billion by 2030.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced key leadership changes, appointing Cary J. Claiborne as President and CEO, succeeding William Stilley, who will lead Adial's subsidiary, Purnovate. Kevin Schuyler has been appointed Chairman of the Board. Claiborne's extensive experience includes previous roles at Indivior PLC and Sucampo Pharmaceuticals. The leadership transition aligns with Adial's goal to advance its lead drug, AD04, which aims to treat Alcohol Use Disorder. The firm plans to engage with regulatory bodies regarding promising Phase 3 trial results and explore partnership opportunities.
Adial Pharmaceuticals reported positive topline results from its ONWARD Phase 3 trial for AD04, targeting Alcohol Use Disorder (AUD). The trial indicated a statistically significant reduction in heavy drinking days among certain patients. The company plans to submit results to both the FDA and EMA while exploring partnership opportunities. As of June 30, 2022, cash and cash equivalents stood at $9.2 million, up from $6.1 million at the end of 2021. AD04's market potential is estimated to be multi-billion dollars in the U.S. alone.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced successful results from its ONWARD trial, demonstrating a significant reduction in heavy drinking days among patients with Alcohol Use Disorder (AUD). AD04, the company's investigational drug, achieved a 79% reduction in heavy drinking days and an 84% decline in AUD severity compared to placebo. These results support the drug's safety and tolerability. Adial plans to submit these findings to regulatory agencies in Europe and the U.S. for product approval and is considering strategic partnerships for further development.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is set to report topline results from its ONWARD™ Phase 3 clinical trial on July 20, 2022. The trial assesses the efficacy and safety of AD04 in treating Alcohol Use Disorder in genetically screened patients. Conducted across 25 sites in six countries, it includes heavy and very heavy drinkers. Previous Phase 2b results indicated significant reductions in drinking frequency and quantity without serious safety concerns. The ongoing research may expand to other addictive disorders, highlighting the drug's potential impact.
